These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 23151129)

  • 1. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.
    Devine T; Dai MS
    Curr Pharm Des; 2013; 19(18):3248-62. PubMed ID: 23151129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of ubiquitin proteasome pathway in cancer development.
    Yerlikaya A; Yöntem M
    Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of MdmX on Mdm2-mediated downregulation of pRB.
    Uchida C; Miwa S; Isobe T; Kitagawa K; Hattori T; Oda T; Yasuda H; Kitagawa M
    FEBS Lett; 2006 Mar; 580(7):1753-8. PubMed ID: 16510145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.
    Allende-Vega N; Saville MK
    Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics in the p53-Mdm2 ubiquitination pathway.
    Brooks CL; Gu W
    Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
    Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
    Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.
    Sparks A; Dayal S; Das J; Robertson P; Menendez S; Saville MK
    Oncogene; 2014 Sep; 33(38):4685-96. PubMed ID: 24121268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
    Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
    Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of p53 degradation via MDM2-mediated ubiquitylation and the ubiquitin-proteasome system during reperfusion after stroke: role of oxidative stress.
    Saito A; Hayashi T; Okuno S; Nishi T; Chan PH
    J Cereb Blood Flow Metab; 2005 Feb; 25(2):267-80. PubMed ID: 15678128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.
    Hjerpe R; Aillet F; Lopitz-Otsoa F; Lang V; Torres-Ramos M; Farrás R; Hay RT; Rodríguez MS
    Int J Biochem Cell Biol; 2010 May; 42(5):725-35. PubMed ID: 20080206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limiting the power of p53 through the ubiquitin proteasome pathway.
    Pant V; Lozano G
    Genes Dev; 2014 Aug; 28(16):1739-51. PubMed ID: 25128494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
    Herman AG; Hayano M; Poyurovsky MV; Shimada K; Skouta R; Prives C; Stockwell BR
    Cancer Discov; 2011 Sep; 1(4):312-25. PubMed ID: 22586610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.